^
Association details:
| Biomarker: | MSI-H/dMMR + KRAS wild-type + BRAF wild-type |
|---|---|
| Cancer: | Colon Cancer |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) + Yervoy (ipilimumab) (CTLA4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Complete pathologic response after laparoscopic hepatectomy following treatment with nivolumab and ipilimumab for anticancer drug-resistant MSI-high colon cancer liver metastasis consisting of poorly differentiated adenocarcinoma with squamous differentiation: A case report
Published date:
10/24/2023
Excerpt:
Genetic examination revealed MSI-high, KRAS wild type, and BRAF wild type....As a second-line treatment, nivolumab and ipilimumab combination therapy was started. After three cycles of these therapy, both of these tumors shrinkage were observed.
DOI:
10.1007/s12328-023-01855-1
